434 related articles for article (PubMed ID: 19171629)
1. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children.
Mosholder AD; Gelperin K; Hammad TA; Phelan K; Johann-Liang R
Pediatrics; 2009 Feb; 123(2):611-6. PubMed ID: 19171629
[TBL] [Abstract][Full Text] [Related]
2. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age.
Blumer JL; Findling RL; Shih WJ; Soubrane C; Reed MD
Pediatrics; 2009 May; 123(5):e770-6. PubMed ID: 19403468
[TBL] [Abstract][Full Text] [Related]
3. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
Johann-Liang R; Wyeth J; Chen M; Cope JU
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
[TBL] [Abstract][Full Text] [Related]
4. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
Wernicke JF; Holdridge KC; Jin L; Edison T; Zhang S; Bangs ME; Allen AJ; Ball S; Dunn D
Dev Med Child Neurol; 2007 Jul; 49(7):498-502. PubMed ID: 17593120
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
6. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
Brams M; Mao AR; Doyle RL
Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
[TBL] [Abstract][Full Text] [Related]
7. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
[TBL] [Abstract][Full Text] [Related]
8. Adderall XR: long acting stimulant for single daily dosing.
Sallee FR; Smirnoff AV
Expert Rev Neurother; 2004 Nov; 4(6):927-34. PubMed ID: 15853519
[TBL] [Abstract][Full Text] [Related]
9. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
11. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
12. Attention-deficit/hyperactivity disorder: how much responsibility are pediatricians taking?
Stein RE; Horwitz SM; Storfer-Isser A; Heneghan AM; Hoagwood KE; Kelleher KJ; O'Connor KG; Olson L
Pediatrics; 2009 Jan; 123(1):248-55. PubMed ID: 19117889
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
Kahbazi M; Ghoreishi A; Rahiminejad F; Mohammadi MR; Kamalipour A; Akhondzadeh S
Psychiatry Res; 2009 Aug; 168(3):234-7. PubMed ID: 19439364
[TBL] [Abstract][Full Text] [Related]
16. Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder.
Chertin B; Koulikov D; Abu-Arafeh W; Mor Y; Shenfeld OZ; Farkas A
J Urol; 2007 Oct; 178(4 Pt 2):1744-7. PubMed ID: 17707010
[TBL] [Abstract][Full Text] [Related]
17. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
18. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
[TBL] [Abstract][Full Text] [Related]
19. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
Warshaw EM; Paller AS; Fowler JF; Zirwas MJ
Clin Ther; 2008 Feb; 30(2):326-37. PubMed ID: 18343271
[TBL] [Abstract][Full Text] [Related]
20. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
